ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1637

Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease: Relation with Neoplasms and Role as a Paraneoplastic Syndrome

Pablo Muñoz Martínez1, Claudia Fernandez Ruiz2, Elena Grau García3, Samuel Leal Rodriguez3, José Ivorra-Cortés4, Carmen Riesco Barcena5, Anderson Huaylla Quispe5, Laura Mas Sánchez6, Daniel Ramos Castro5, Alba Torrat noves7, Iago Alcantara Alvarez8, Belén Villanueva Mañés8, Miguel Simeo Vinaixa8, Andrés Pérez Hurtado5 and Jose A Román-Ivorra9, 1Hospital Universitario y Politècnico La Fe, Sagunto, Spain, 2Escuela de Doctorado. UCV, Valencia, Comunidad Valenciana, Spain, 3HUP La Fe, Valencia, Spain, 4Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, 5Rheumatology Department. HUP La Fe, Valencia, Spain, 6Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, 7Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, 8Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, 9Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain

Meeting: ACR Convergence 2024

Keywords: giant cell arteritis, Polymyalgia Rheumatica (PMR)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: The dysregulation of the immune system inherent in inflammatory diseases may contribute to the development of neoplasms. However, the relationship between the giant cell arteritis-polymyalgia rheumatica spectrum disease (GPSD) and malignancy is still under debate.

Our aim is to determine the incidence rate of neoplasms among the GPSD population and compare it with the Spanish general population, as well as to identify its role as a paraneoplastic syndrome in terms of temporal criteria.

Methods: An observational, single-center, longitudinal study on GPSD patients (2015-2023) was conducted. Demographic, clinical variables and neoplasms found after GPSD diagnosis (excluding metastatic events or recurrences and non-melanoma skin cancer) were collected. The crude incidence rate of neoplasms in Spain was obtained from the Global Cancer Observatory (GLOBOCAN). In order to adjust by age and sex, we performed an indirect standardization method and calculated the standardized neoplasm ratio (SNR) and standardized incidence ratio (SIR).

Results: A total of 334 GPSD patients were included (66 % women) with a mean age at diagnosis of 73 (8) years old. As a comparative group, we studied the Spanish population older than 50 years old. We found 16 neoplasms in the GPSD group (table 1). The most common types were from digestive system and prostate cancer. Any variable was significantly related with the development of neoplasm after using the bivariate and multivariate analysis.

Out of the 16 neoplasms, 11 (68,75%) were diagnosed within the first two years, specially during the first year (7). The 5 remaining appeared from the fourth year after GPSD diagnosis (figure 1).

The GPSD group showed an incidence rate of neoplasms (IRN) of 1282 (CI 95% 487-2076) per 100,000 person-years (p-y) for women and of 1534 (CI 95% 306-2761) per 100,000 p-y for men.

The SNR was 4.03 (CI 95% 1.53-6.53) in women and 2.37 (CI 95% 0.47-4.27) in men. Considering the neoplasms diagnosed in the two first years, the SNR were 2.42 (CI 95% 0.484-4.356) in women and 2.108 (CI 95% 0.258-3.868) in men (table 2).  

The SIR was 3646.75 (CI 95% 1384.85-5908.65) in women and 3547.49 (CI 95% 650.99-6444.29) for men. If we consider the neoplasms diagnosed in the two first years, the SIR was 2189.86 (CI 95% 832.59-3548.13) in women and 3153.99 (CI 95% 394.25-5913.73) in men (table 2).  

Conclusion: We observed a high incidence rate of neoplasms in our GPSD patients. For women, incidence was significantly higher than in the general population.  For men and neoplasms developed two years after the diagnosis, incidence was higher than in the general population, but the difference was not statistically significant. Most of the neoplasms were diagnosed within the first two years, especially during the first.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: P. Muñoz Martínez: None; C. Fernandez Ruiz: None; E. Grau García: None; S. Leal Rodriguez: None; J. Ivorra-Cortés: None; C. Riesco Barcena: None; A. Huaylla Quispe: None; L. Mas Sánchez: None; D. Ramos Castro: None; A. Torrat noves: None; I. Alcantara Alvarez: None; B. Villanueva Mañés: None; M. Simeo Vinaixa: None; A. Pérez Hurtado: None; J. Román-Ivorra: None.

To cite this abstract in AMA style:

Muñoz Martínez P, Fernandez Ruiz C, Grau García E, Leal Rodriguez S, Ivorra-Cortés J, Riesco Barcena C, Huaylla Quispe A, Mas Sánchez L, Ramos Castro D, Torrat noves A, Alcantara Alvarez I, Villanueva Mañés B, Simeo Vinaixa M, Pérez Hurtado A, Román-Ivorra J. Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease: Relation with Neoplasms and Role as a Paraneoplastic Syndrome [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/giant-cell-arteritis-polymyalgia-rheumatica-spectrum-disease-relation-with-neoplasms-and-role-as-a-paraneoplastic-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/giant-cell-arteritis-polymyalgia-rheumatica-spectrum-disease-relation-with-neoplasms-and-role-as-a-paraneoplastic-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology